The FDA recently announced its plan to phase out the animal testing requirement for monoclonal antibodies (mAbs) and other drugs, instead opting to use human-relevant new approach methodologies (NAMs) ...

South Africa’s Black woman-founded S.MAB Group appoints new CEO, keeping leadership in women’s hands. South Africa’s pioneering Black woman-founded S.MAB Group has appointed a new CEO, continuing its ...

Shares of Y-mAbs Therapeutics soared after the company said it would be acquired by SERB Pharmaceuticals in an all-cash deal worth double Monday's closing price. The stock more than doubled Tuesday to ...

Y-mAbs Therapeutics (NASDAQ:YMAB) is set to go private after SERB Pharmaceuticals announced on Tuesday that it would buy the cancer drug developer for an estimated $412M in equity value. The stock ...

(RTTNews) - SERB Pharmaceuticals (SERB), and Y-mAbs Therapeutics, Inc. (YMAB) have entered into a definitive merger agreement under which SERB will acquire Y-mAbs, including its lead commercial ...

After Y-mAbs Therapeutics won its first FDA approval more than four years ago, the company has faced numerous hurdles on its quest to become an oncology powerhouse. Now, the drugmaker is moving to ...

For decades, therapeutic monoclonal antibody (mAb) production relied on traditional batch-based manufacturing using stainless steel systems. But as biopharmaceutical pipelines grow to meet rising ...

Y-mAbs Therapeutics (NASDAQ:YMAB) lost ~6% on Tuesday after Bank of America downgraded the cancer drug developer to Underperform from Neutral, arguing that most of the market potential for the company ...

Innovative bioprocessing technologies are needed to make monoclonal antibody (mAb) production cheaper, according to new research, which suggests lowering the cost of goods (COGs) for mAb-based ...

CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders. Its ...

I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline ...

Y-mAbs Therapeutics is parting ways with its chief commercial officer and putting a new hire in charge of the cancer drug Danyelza. The biotech made the changes, which include “a small adjustment” to ...